HUP0400251A3 - 5-ht receptor ligands and uses thereof and pharmaceutical compositions containing them - Google Patents
5-ht receptor ligands and uses thereof and pharmaceutical compositions containing themInfo
- Publication number
- HUP0400251A3 HUP0400251A3 HU0400251A HUP0400251A HUP0400251A3 HU P0400251 A3 HUP0400251 A3 HU P0400251A3 HU 0400251 A HU0400251 A HU 0400251A HU P0400251 A HUP0400251 A HU P0400251A HU P0400251 A3 HUP0400251 A3 HU P0400251A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- receptor ligands
- ligands
- receptor
- Prior art date
Links
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29995301P | 2001-06-21 | 2001-06-21 | |
PCT/IB2002/002293 WO2003000666A1 (en) | 2001-06-21 | 2002-06-17 | 5-ht receptor ligands and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400251A2 HUP0400251A2 (hu) | 2004-08-30 |
HUP0400251A3 true HUP0400251A3 (en) | 2006-02-28 |
Family
ID=23157027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400249A HUP0400249A3 (en) | 2001-06-21 | 2002-06-17 | Pyridine derivatives as 5-ht receptor ligands and uses thereof |
HU0400251A HUP0400251A3 (en) | 2001-06-21 | 2002-06-17 | 5-ht receptor ligands and uses thereof and pharmaceutical compositions containing them |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400249A HUP0400249A3 (en) | 2001-06-21 | 2002-06-17 | Pyridine derivatives as 5-ht receptor ligands and uses thereof |
Country Status (39)
Country | Link |
---|---|
US (6) | US6825198B2 (hu) |
EP (2) | EP1401819A1 (hu) |
JP (2) | JP2004534823A (hu) |
KR (2) | KR20040010767A (hu) |
CN (2) | CN1745074A (hu) |
AP (1) | AP2002002561A0 (hu) |
AR (1) | AR036095A1 (hu) |
AU (1) | AU2002309173B2 (hu) |
BG (2) | BG108491A (hu) |
BR (2) | BR0210471A (hu) |
CA (2) | CA2450491A1 (hu) |
CR (1) | CR7168A (hu) |
CZ (2) | CZ20033508A3 (hu) |
DO (1) | DOP2002000412A (hu) |
EA (2) | EA200301213A1 (hu) |
EC (2) | ECSP034881A (hu) |
EE (2) | EE200400025A (hu) |
GE (1) | GEP20053655B (hu) |
GT (1) | GT200200120A (hu) |
HR (1) | HRP20031042A2 (hu) |
HU (2) | HUP0400249A3 (hu) |
IL (2) | IL158807A0 (hu) |
IS (2) | IS7040A (hu) |
MA (2) | MA27036A1 (hu) |
MX (2) | MXPA03011941A (hu) |
NO (2) | NO20035697D0 (hu) |
NZ (1) | NZ529542A (hu) |
OA (2) | OA12621A (hu) |
PA (1) | PA8548901A1 (hu) |
PE (1) | PE20030268A1 (hu) |
PL (2) | PL367777A1 (hu) |
SK (2) | SK15672003A3 (hu) |
SV (1) | SV2003001102A (hu) |
TN (2) | TNSN03142A1 (hu) |
UA (1) | UA74443C2 (hu) |
UY (1) | UY27343A1 (hu) |
WO (2) | WO2003000666A1 (hu) |
YU (1) | YU95303A (hu) |
ZA (2) | ZA200308843B (hu) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
EA008148B1 (ru) * | 2002-06-19 | 2007-04-27 | Биовитрум Аб | Новые соединения, их применение и получение |
US7226925B2 (en) | 2002-06-19 | 2007-06-05 | Biovitrum Ab | Compounds, their use and preparation |
WO2004065380A1 (en) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ES2308139T3 (es) * | 2003-01-29 | 2008-12-01 | Asterand Uk Limited | Antagonista de receptos ep4. |
ES2401330T3 (es) | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
US20040235856A1 (en) * | 2003-04-25 | 2004-11-25 | Pfizer Inc | Treatment of incontinence |
CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
US20080146583A1 (en) * | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
NZ578503A (en) | 2003-06-17 | 2011-02-25 | Arena Pharm Inc | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
EP1636191A2 (en) | 2003-06-17 | 2006-03-22 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
KR20060065584A (ko) * | 2003-06-20 | 2006-06-14 | 아레나 파마슈티칼스, 인크. | N-페닐-피페라진 유도체 및 5ht2c 수용체 관련 질환의예방 또는 치료 방법 |
JP4920410B2 (ja) | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療 |
US7390907B2 (en) | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2005053688A1 (en) | 2003-11-26 | 2005-06-16 | Alcon, Inc. | Substituted furo[2,3-g] indazoles for the treatment of glaucoma |
US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
EP1694670A1 (en) * | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
SI1756084T1 (sl) * | 2004-06-04 | 2009-04-30 | Arena Pharm Inc | Substituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi s tem |
EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
US8114502B2 (en) * | 2004-09-02 | 2012-02-14 | 3M Innovative Properties Company | Substrates with multiple images |
AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US20090156474A1 (en) * | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
BRPI0517737A (pt) | 2004-11-17 | 2008-10-21 | Miikana Therapeutics Inc | inibidores de quinase |
JPWO2006064780A1 (ja) * | 2004-12-14 | 2008-06-12 | 塩野義製薬株式会社 | 便秘治療剤 |
CN102321023A (zh) | 2004-12-21 | 2012-01-18 | 艾尼纳制药公司 | (r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓盐酸盐的晶型 |
SI1833473T1 (sl) * | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe |
EP1856075A1 (en) * | 2005-01-25 | 2007-11-21 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
BRPI0609268A2 (pt) * | 2005-03-31 | 2010-03-09 | Pfizer Prod Inc | derivados de ciclopentapiridina e tetraidroquinolina |
US7594976B2 (en) * | 2005-05-13 | 2009-09-29 | 3M Innovative Properties Company | Methods of manufacturing substrates |
KR20080047375A (ko) | 2005-07-29 | 2008-05-28 | 콘서트 파마슈티컬즈, 인크. | 약제 화합물 |
KR101487027B1 (ko) * | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
CA2632286C (en) * | 2005-12-05 | 2011-11-15 | Pfizer Products Inc. | Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer |
DK1963302T3 (da) * | 2005-12-05 | 2013-04-02 | Pfizer Prod Inc | Polymorfer af en C-MET/HGFR-inhibitor |
CA2634235A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
WO2007120517A2 (en) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
BRPI0711740A2 (pt) * | 2006-05-30 | 2011-12-06 | Hoffmann La Roche | compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos |
CA2657640A1 (en) * | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
AU2007320906A1 (en) | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
PL2848610T3 (pl) | 2006-11-15 | 2018-01-31 | Ym Biosciences Australia Pty | Inhibitory aktywności kinazy |
EP2099743B1 (en) | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
DK2118279T3 (en) | 2007-01-16 | 2018-02-26 | Ipintl Llc | HIS UNKNOWN COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME |
US20080220104A1 (en) * | 2007-03-08 | 2008-09-11 | Cappello John V | Compositions for producing satiety |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
EP2288585A1 (en) * | 2008-03-04 | 2011-03-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
PE20110061A1 (es) | 2008-06-12 | 2011-01-31 | Janssen Pharmaceutica Nv | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina |
EP2303275A4 (en) * | 2008-06-17 | 2012-05-09 | Univ Duke | STANDARD RECEPTOR MODULATORS |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
WO2010148207A2 (en) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
JP6053519B2 (ja) * | 2009-06-26 | 2016-12-27 | サノフイ | ヒスタミンh3受容体アンタゴニストの新規なフマル酸塩 |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
KR20130112848A (ko) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | 5-ht2c 수용체 아고니스트의 제조 방법 |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
CN103037969B (zh) * | 2010-06-23 | 2015-07-29 | 约翰森·马瑟公开有限公司 | 络合物 |
US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
EP2611427B1 (en) | 2010-09-01 | 2018-10-17 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
US9365521B2 (en) | 2010-09-01 | 2016-06-14 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-HT2C agonists |
EP2611782A1 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
BR112013019942B1 (pt) * | 2011-02-25 | 2022-01-11 | Yuhan Corporation | Uso de composto ou de seu sal farmaceuticamente aceitável, composição farmacêutica, compostos ou seus sais farmaceuticamente aceitáveis e respectivos processos de preparação |
KR20150023318A (ko) * | 2012-05-30 | 2015-03-05 | 에프. 호프만-라 로슈 아게 | 피롤리디노 헤테로사이클 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
CA2886875A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
CN105142624A (zh) | 2013-01-10 | 2015-12-09 | 普尔莫凯恩股份有限公司 | 非选择性激酶抑制剂 |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN111743901B (zh) | 2013-10-11 | 2023-09-12 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
JP2020500183A (ja) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
MX2021010753A (es) * | 2019-03-07 | 2021-12-15 | Arbormentis LLC | Composiciones y métodos de uso que comprenden sustancias con acciones de plasticidad neural administradas a dosificaciones y formulaciones no psicodélicas/psicotomiméticas. |
CN111704582B (zh) * | 2020-06-23 | 2021-06-11 | 杭州煌森生物科技有限公司 | 一种法匹拉韦及其衍生物的制备方法 |
CN115618396B (zh) * | 2022-11-28 | 2023-04-07 | 云账户技术(天津)有限公司 | 一种数据的加密方法及装置 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127996C (hu) | 1963-11-19 | |||
US3980781A (en) * | 1966-03-31 | 1976-09-14 | Imperial Chemical Industries Limited | Fungicidal composition and method containing 2-amino-pyrimidines |
GB1165283A (en) * | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
FR2281117A2 (fr) | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
US4166852A (en) | 1974-08-09 | 1979-09-04 | Produits Chimiques Ugine Kuhlmann | Piperazino-pyrimidines and their use as spasmolytic agents |
US4081542A (en) | 1975-04-21 | 1978-03-28 | Merck & Co., Inc. | Piperazinylpyrazines |
SE421695B (sv) * | 1975-04-21 | 1982-01-25 | Merck & Co Inc | Sett att framstella piperazinylpyraziner |
FR2311776A1 (fr) | 1975-05-23 | 1976-12-17 | Sogeras | Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation |
FI70411C (fi) | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
DE3905364A1 (de) | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
JPH0665203A (ja) | 1992-06-25 | 1994-03-08 | Elf Sanofi | ピペラジンのヘテロ環誘導体 |
EP0662962A1 (en) | 1992-09-28 | 1995-07-19 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
EP0723533A1 (en) | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
US5419301A (en) * | 1994-04-14 | 1995-05-30 | Ford Motor Company | Adaptive control of camless valvetrain |
WO1996031488A1 (fr) * | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux derives de pyrimidine efficaces en tant que medicament psychotrope et leur procede de fabrication |
US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
EP0791355B1 (en) | 1996-02-29 | 2002-04-17 | Pfizer Inc. | Method of reducing tissue damage associated with ischemia |
US6326368B1 (en) | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
KR100239800B1 (ko) * | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
DE19710435A1 (de) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
WO2000028993A1 (en) | 1998-11-19 | 2000-05-25 | Nortran Pharmaceuticals, Inc. | Serotonin ligands as pro-erectile compounds |
GB9902047D0 (en) | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
EA005820B1 (ru) | 1999-05-21 | 2005-06-30 | Биовитрум Аб | Агонисты и антагонисты рецепторов 5-ht |
SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
DE60142355D1 (de) | 2000-11-20 | 2010-07-22 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor |
IL155875A0 (en) | 2000-11-20 | 2003-12-23 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
-
2002
- 2002-05-28 US US10/156,884 patent/US6825198B2/en not_active Expired - Fee Related
- 2002-06-05 US US10/163,881 patent/US6894050B2/en not_active Expired - Fee Related
- 2002-06-05 DO DO2002000412A patent/DOP2002000412A/es unknown
- 2002-06-14 GT GT200200120A patent/GT200200120A/es unknown
- 2002-06-17 MX MXPA03011941A patent/MXPA03011941A/es unknown
- 2002-06-17 HU HU0400249A patent/HUP0400249A3/hu unknown
- 2002-06-17 CA CA002450491A patent/CA2450491A1/en not_active Abandoned
- 2002-06-17 YU YU95303A patent/YU95303A/sh unknown
- 2002-06-17 HU HU0400251A patent/HUP0400251A3/hu unknown
- 2002-06-17 EA EA200301213A patent/EA200301213A1/ru unknown
- 2002-06-17 PL PL02367777A patent/PL367777A1/xx not_active Application Discontinuation
- 2002-06-17 CZ CZ20033508A patent/CZ20033508A3/cs unknown
- 2002-06-17 IL IL15880702A patent/IL158807A0/xx unknown
- 2002-06-17 GE GE5389A patent/GEP20053655B/en unknown
- 2002-06-17 WO PCT/IB2002/002293 patent/WO2003000666A1/en not_active Application Discontinuation
- 2002-06-17 EE EEP200400025A patent/EE200400025A/xx unknown
- 2002-06-17 CZ CZ20033431A patent/CZ20033431A3/cs unknown
- 2002-06-17 TN TNPCT/IB2002/002293A patent/TNSN03142A1/fr unknown
- 2002-06-17 NZ NZ529542A patent/NZ529542A/en unknown
- 2002-06-17 BR BR0210471-7A patent/BR0210471A/pt not_active IP Right Cessation
- 2002-06-17 EP EP02735853A patent/EP1401819A1/en not_active Withdrawn
- 2002-06-17 MX MXPA03011940A patent/MXPA03011940A/es active IP Right Grant
- 2002-06-17 KR KR10-2003-7016704A patent/KR20040010767A/ko not_active Application Discontinuation
- 2002-06-17 JP JP2003507068A patent/JP2004534823A/ja not_active Withdrawn
- 2002-06-17 EE EEP200400026A patent/EE200400026A/xx unknown
- 2002-06-17 OA OA1200300319A patent/OA12621A/en unknown
- 2002-06-17 CN CNA028125541A patent/CN1745074A/zh active Pending
- 2002-06-17 KR KR1020037016699A patent/KR100566854B1/ko not_active IP Right Cessation
- 2002-06-17 CN CNA028137345A patent/CN1630645A/zh active Pending
- 2002-06-17 UA UA20031211976A patent/UA74443C2/uk unknown
- 2002-06-17 SK SK1567-2003A patent/SK15672003A3/sk unknown
- 2002-06-17 WO PCT/IB2002/002261 patent/WO2003000663A1/en active IP Right Grant
- 2002-06-17 JP JP2003507071A patent/JP2005501821A/ja not_active Abandoned
- 2002-06-17 EP EP02735869A patent/EP1401820A1/en not_active Withdrawn
- 2002-06-17 TN TNPCT/IB2002/002261A patent/TNSN03143A1/fr unknown
- 2002-06-17 EA EA200301215A patent/EA007183B1/ru not_active IP Right Cessation
- 2002-06-17 PL PL02367746A patent/PL367746A1/xx not_active Application Discontinuation
- 2002-06-17 CA CA002455292A patent/CA2455292A1/en not_active Abandoned
- 2002-06-17 SK SK1571-2003A patent/SK15712003A3/sk not_active Application Discontinuation
- 2002-06-17 OA OA1200300330A patent/OA12629A/en unknown
- 2002-06-17 IL IL15880802A patent/IL158808A0/xx unknown
- 2002-06-17 BR BR0210503-9A patent/BR0210503A/pt not_active IP Right Cessation
- 2002-06-17 AU AU2002309173A patent/AU2002309173B2/en not_active Ceased
- 2002-06-19 AR ARP020102299A patent/AR036095A1/es unknown
- 2002-06-19 PE PE2002000529A patent/PE20030268A1/es not_active Application Discontinuation
- 2002-06-20 SV SV2002001102A patent/SV2003001102A/es not_active Application Discontinuation
- 2002-06-20 AP APAP/P/2002/002561A patent/AP2002002561A0/en unknown
- 2002-06-20 UY UY27343A patent/UY27343A1/es not_active Application Discontinuation
- 2002-06-21 PA PA20028548901A patent/PA8548901A1/es unknown
-
2003
- 2003-11-13 ZA ZA200308843A patent/ZA200308843B/en unknown
- 2003-11-13 ZA ZA200308842A patent/ZA200308842B/en unknown
- 2003-11-17 IS IS7040A patent/IS7040A/is unknown
- 2003-11-17 IS IS7041A patent/IS7041A/is unknown
- 2003-11-25 CR CR7168A patent/CR7168A/es not_active Application Discontinuation
- 2003-12-08 EC EC2003004881A patent/ECSP034881A/es unknown
- 2003-12-09 EC EC2003004884A patent/ECSP034884A/es unknown
- 2003-12-10 MA MA27432A patent/MA27036A1/fr unknown
- 2003-12-10 MA MA27431A patent/MA27035A1/fr unknown
- 2003-12-16 HR HR20031042A patent/HRP20031042A2/hr not_active Application Discontinuation
- 2003-12-19 NO NO20035697A patent/NO20035697D0/no not_active Application Discontinuation
- 2003-12-19 NO NO20035698A patent/NO20035698L/no not_active Application Discontinuation
- 2003-12-22 BG BG108491A patent/BG108491A/xx unknown
- 2003-12-22 BG BG108495A patent/BG108495A/xx unknown
-
2004
- 2004-08-19 US US10/922,198 patent/US20050020604A1/en not_active Abandoned
- 2004-08-19 US US10/922,058 patent/US20050090503A1/en not_active Abandoned
- 2004-09-16 US US10/942,346 patent/US20050054656A1/en not_active Abandoned
- 2004-09-16 US US10/942,345 patent/US6995159B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400251A3 (en) | 5-ht receptor ligands and uses thereof and pharmaceutical compositions containing them | |
HUP0401924A3 (en) | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them | |
HUP0304060A3 (en) | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them | |
HUP0500870A3 (en) | Nitrogen containing heterocyclic malanocortin receptor ligands, pharmaceutical compositions containing them and their use | |
HUP0400467A3 (en) | 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use | |
EP1450824A4 (en) | PHARMACEUTICAL COMPOSITION | |
HUP0400974A3 (en) | Peptide-based compounds and pharmaceutical compositions containing them | |
IL161616A0 (en) | Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
HUP0401333A3 (en) | Spiropyrazole compounds and pharmaceutical compositions containing them | |
IL158044A0 (en) | Cyclopropylindole derivatives and pharmaceutical compositions containing the same | |
IL158300A0 (en) | Bisarylimidazol derivatives and pharmaceutical compositions containing the same | |
IL156812A0 (en) | Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same | |
IL158898A0 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF | |
HUP0303163A3 (en) | Tramadol-based pharmaceutical composition | |
GB0117057D0 (en) | Pharmaceutical composition | |
HUP0500024A3 (en) | 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them | |
EP1408896A4 (en) | PHARMACEUTICAL COMPOSITION | |
HUP0400179A3 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them | |
GB0129117D0 (en) | Pharmaceutical composition | |
HUP0401644A3 (en) | Aminobenzoephenones, pharmaceutical compositions containing them and use thereof | |
HUP0303469A3 (en) | Phtalazinon-derivatives, their use and pharmaceutical compositions containing them | |
GB0116107D0 (en) | Pharmaceutical composition | |
HUP0401713A3 (en) | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | |
HUP0400043A3 (en) | Oxazol/thiazol-derivatives activators of the hppar-alpha receptor and pharmaceutical compositions containing them | |
GB0127805D0 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |